Blood cancer therapy PKC412 shows promise in EBS cells: Study
PKC412, a medication already used for treating certain blood cancers, has the potential to be repurposed for treating epidermolysis bullosa simplex (EBS), according to a preclinical study. Using skin cells from people with various EBS-causing genetic mutations, scientists found that PKC412, also known as midostaurin, made the cells more…